Cargando…

Overexpression of miR-21-5p as a predictive marker for complete tumor regression to neoadjuvant chemoradiotherapy in rectal cancer patients

BACKGROUND: Neoadjuvant chemoradiotherapy (nCRT) followed by radical surgery is the preferred treatment strategy for locally advanced rectal cancer. However, complete tumor regression is observed in a significant proportion of patients after nCRT, making them ideal candidates for alternative treatme...

Descripción completa

Detalles Bibliográficos
Autores principales: Lopes-Ramos, Camila Miranda, Habr-Gama, Angelita, Quevedo, Bruna de Souza, Felício, Natália Mariana, Bettoni, Fabiana, Koyama, Fernanda Christtanini, Asprino, Paula Fontes, Galante, Pedro Alexandre, Gama-Rodrigues, Joaquim, Camargo, Anamaria Aranha, Perez, Rodrigo Oliva, Parmigiani, Raphael Bessa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4279677/
https://www.ncbi.nlm.nih.gov/pubmed/25496125
http://dx.doi.org/10.1186/s12920-014-0068-7
_version_ 1782350743491051520
author Lopes-Ramos, Camila Miranda
Habr-Gama, Angelita
Quevedo, Bruna de Souza
Felício, Natália Mariana
Bettoni, Fabiana
Koyama, Fernanda Christtanini
Asprino, Paula Fontes
Galante, Pedro Alexandre
Gama-Rodrigues, Joaquim
Camargo, Anamaria Aranha
Perez, Rodrigo Oliva
Parmigiani, Raphael Bessa
author_facet Lopes-Ramos, Camila Miranda
Habr-Gama, Angelita
Quevedo, Bruna de Souza
Felício, Natália Mariana
Bettoni, Fabiana
Koyama, Fernanda Christtanini
Asprino, Paula Fontes
Galante, Pedro Alexandre
Gama-Rodrigues, Joaquim
Camargo, Anamaria Aranha
Perez, Rodrigo Oliva
Parmigiani, Raphael Bessa
author_sort Lopes-Ramos, Camila Miranda
collection PubMed
description BACKGROUND: Neoadjuvant chemoradiotherapy (nCRT) followed by radical surgery is the preferred treatment strategy for locally advanced rectal cancer. However, complete tumor regression is observed in a significant proportion of patients after nCRT, making them ideal candidates for alternative treatment strategies to this considerably morbid procedure. Identification of such patients based on clinical findings (complete clinical response - cCR) is difficult mainly because it relies on subjective clinical and imaging studies. Our goal was to identify biomarkers capable of predicting complete response to nCRT. METHODS: We analyzed miRNA expression profile using deep sequencing in rectal tumor biopsies prior to nCRT. Differential expression was investigated by EdgeR for a training (n = 27) and a validation (n = 16) set of patients to identify miRNAs associated with treatment response (complete vs. incomplete). In vitro experiments with two cancer cell lines were also performed in order to evaluate the possible role of miRNAs on response to nCRT. RESULTS: We found 4 miRNAs differentially expressed between complete and incomplete responders to nCRT. In addition, validation was performed using an independent group of patients and miR-21-5p was confirmed as being overexpressed in complete responders. Overall sensitivity and specificity of miR-21-5p expression in predicting complete response to nCRT was 78% and 86% respectively. Interestingly, in a subset of patients with cCR followed by early local recurrence, the expression level of miR-21-5p was considerably low, similarly to incomplete responders. We also found SATB1, a miR-21-5p target gene and known multidrug resistance gene, whose expression was inversely correlated with miR-21-5p expression. Finally, we performed functional experiments and showed that miR-21-5p and SATB1 may be directly involved with poor response to nCRT in rectal cancer patients. CONCLUSIONS: This study suggests miR-21-5p as a promising predictive biomarker, which should aid in the selection of patients with cCR to nCRT that potentially could be spared from radical surgery. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12920-014-0068-7) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4279677
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-42796772014-12-31 Overexpression of miR-21-5p as a predictive marker for complete tumor regression to neoadjuvant chemoradiotherapy in rectal cancer patients Lopes-Ramos, Camila Miranda Habr-Gama, Angelita Quevedo, Bruna de Souza Felício, Natália Mariana Bettoni, Fabiana Koyama, Fernanda Christtanini Asprino, Paula Fontes Galante, Pedro Alexandre Gama-Rodrigues, Joaquim Camargo, Anamaria Aranha Perez, Rodrigo Oliva Parmigiani, Raphael Bessa BMC Med Genomics Research Article BACKGROUND: Neoadjuvant chemoradiotherapy (nCRT) followed by radical surgery is the preferred treatment strategy for locally advanced rectal cancer. However, complete tumor regression is observed in a significant proportion of patients after nCRT, making them ideal candidates for alternative treatment strategies to this considerably morbid procedure. Identification of such patients based on clinical findings (complete clinical response - cCR) is difficult mainly because it relies on subjective clinical and imaging studies. Our goal was to identify biomarkers capable of predicting complete response to nCRT. METHODS: We analyzed miRNA expression profile using deep sequencing in rectal tumor biopsies prior to nCRT. Differential expression was investigated by EdgeR for a training (n = 27) and a validation (n = 16) set of patients to identify miRNAs associated with treatment response (complete vs. incomplete). In vitro experiments with two cancer cell lines were also performed in order to evaluate the possible role of miRNAs on response to nCRT. RESULTS: We found 4 miRNAs differentially expressed between complete and incomplete responders to nCRT. In addition, validation was performed using an independent group of patients and miR-21-5p was confirmed as being overexpressed in complete responders. Overall sensitivity and specificity of miR-21-5p expression in predicting complete response to nCRT was 78% and 86% respectively. Interestingly, in a subset of patients with cCR followed by early local recurrence, the expression level of miR-21-5p was considerably low, similarly to incomplete responders. We also found SATB1, a miR-21-5p target gene and known multidrug resistance gene, whose expression was inversely correlated with miR-21-5p expression. Finally, we performed functional experiments and showed that miR-21-5p and SATB1 may be directly involved with poor response to nCRT in rectal cancer patients. CONCLUSIONS: This study suggests miR-21-5p as a promising predictive biomarker, which should aid in the selection of patients with cCR to nCRT that potentially could be spared from radical surgery. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12920-014-0068-7) contains supplementary material, which is available to authorized users. BioMed Central 2014-12-11 /pmc/articles/PMC4279677/ /pubmed/25496125 http://dx.doi.org/10.1186/s12920-014-0068-7 Text en © Lopes-Ramos et al.; licensee BioMed Central. 2014 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Lopes-Ramos, Camila Miranda
Habr-Gama, Angelita
Quevedo, Bruna de Souza
Felício, Natália Mariana
Bettoni, Fabiana
Koyama, Fernanda Christtanini
Asprino, Paula Fontes
Galante, Pedro Alexandre
Gama-Rodrigues, Joaquim
Camargo, Anamaria Aranha
Perez, Rodrigo Oliva
Parmigiani, Raphael Bessa
Overexpression of miR-21-5p as a predictive marker for complete tumor regression to neoadjuvant chemoradiotherapy in rectal cancer patients
title Overexpression of miR-21-5p as a predictive marker for complete tumor regression to neoadjuvant chemoradiotherapy in rectal cancer patients
title_full Overexpression of miR-21-5p as a predictive marker for complete tumor regression to neoadjuvant chemoradiotherapy in rectal cancer patients
title_fullStr Overexpression of miR-21-5p as a predictive marker for complete tumor regression to neoadjuvant chemoradiotherapy in rectal cancer patients
title_full_unstemmed Overexpression of miR-21-5p as a predictive marker for complete tumor regression to neoadjuvant chemoradiotherapy in rectal cancer patients
title_short Overexpression of miR-21-5p as a predictive marker for complete tumor regression to neoadjuvant chemoradiotherapy in rectal cancer patients
title_sort overexpression of mir-21-5p as a predictive marker for complete tumor regression to neoadjuvant chemoradiotherapy in rectal cancer patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4279677/
https://www.ncbi.nlm.nih.gov/pubmed/25496125
http://dx.doi.org/10.1186/s12920-014-0068-7
work_keys_str_mv AT lopesramoscamilamiranda overexpressionofmir215pasapredictivemarkerforcompletetumorregressiontoneoadjuvantchemoradiotherapyinrectalcancerpatients
AT habrgamaangelita overexpressionofmir215pasapredictivemarkerforcompletetumorregressiontoneoadjuvantchemoradiotherapyinrectalcancerpatients
AT quevedobrunadesouza overexpressionofmir215pasapredictivemarkerforcompletetumorregressiontoneoadjuvantchemoradiotherapyinrectalcancerpatients
AT felicionataliamariana overexpressionofmir215pasapredictivemarkerforcompletetumorregressiontoneoadjuvantchemoradiotherapyinrectalcancerpatients
AT bettonifabiana overexpressionofmir215pasapredictivemarkerforcompletetumorregressiontoneoadjuvantchemoradiotherapyinrectalcancerpatients
AT koyamafernandachristtanini overexpressionofmir215pasapredictivemarkerforcompletetumorregressiontoneoadjuvantchemoradiotherapyinrectalcancerpatients
AT asprinopaulafontes overexpressionofmir215pasapredictivemarkerforcompletetumorregressiontoneoadjuvantchemoradiotherapyinrectalcancerpatients
AT galantepedroalexandre overexpressionofmir215pasapredictivemarkerforcompletetumorregressiontoneoadjuvantchemoradiotherapyinrectalcancerpatients
AT gamarodriguesjoaquim overexpressionofmir215pasapredictivemarkerforcompletetumorregressiontoneoadjuvantchemoradiotherapyinrectalcancerpatients
AT camargoanamariaaranha overexpressionofmir215pasapredictivemarkerforcompletetumorregressiontoneoadjuvantchemoradiotherapyinrectalcancerpatients
AT perezrodrigooliva overexpressionofmir215pasapredictivemarkerforcompletetumorregressiontoneoadjuvantchemoradiotherapyinrectalcancerpatients
AT parmigianiraphaelbessa overexpressionofmir215pasapredictivemarkerforcompletetumorregressiontoneoadjuvantchemoradiotherapyinrectalcancerpatients